【TianjinZ T14 交流专区】天津中新药业 TIANJIN ZHONG XIN PHARM GROUP

icy97

Tianjin Zhongxin Pharmaceutical Group Corporation Limited is the sole listed company in China that has listed both S-shares in Singapore and A-shares in China. Owning 50 branch companies and subsidiaries with holding and participating stock. Its sales revenue is reached 2.1 billion Yuan RMB a year. The business of Zhongxin covers a wide range of fields including Chinese patent medicines, Chinese medicinal materials, pharmaceutical raw materials and western medicines, bioengineering drugs and nutritious & health products, etc. with nearly 800 product varieties in 20-odd types of preparations being registered. The company has built up wholesale and retail system in various areas of Tianjin Municipality, with a marketing network extending to more than 30 countries and regions as well as all across China. The company¡ˉs key products are Suxiao Jiuxin Wan, Huoxiang Zhengqi Ruan Jiaonang, Zilong Jin Pian, Jinqi Jiangtang Pian, Weichang An Wan, Biqi Jiaonang, |á-2b Interferon, Gliclazide, Te Zi She Fu, etc. and they enjoy high reputation in the medical community. As the company¡ˉs management is being perfected, the company makes some joint venture companies with some well-known pharmaceutical enterprises in the world such as Glax Smithkline America, Teva Israel, Baxter America, Shinpoong Seoul Korea, etc. so as to explore and go forward hand in hand for human health cause.

公司官网：http://www.zhongxinyaoye.com/eng/index.asp

Name of Announcer *	TIANJIN ZHONG XIN PHARM GROUP
Company Registration No.	120000000004711
Announcement submitted on behalf of	TIANJIN ZHONG XIN PHARM GROUP
Announcement is submitted with respect to *	TIANJIN ZHONG XIN PHARM GROUP
Announcement is submitted by *	Jiao Yan
Designation *	Secretary to the Board
Date & Time of Broadcast	15-Aug-2013 01:23:16
Announcement No.	00002

>> ANNOUNCEMENT DETAILS

The details of the announcement start here ...

For the Financial Period Ended *	30-06-2013
Description

Attachments

s2013TZXP2Q20130812.pdf